MENU

NTLA Stock Intellia Therapeutics (NTLA, $22.72) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 28, 2024

A.I.dvisor
at Tickeron.com
05/29/24
Loading...
NTLA - Intellia Therapeutics
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $22.72
Daily change: -$2.12 (-8.53%)
Daily volume: 2M
Capitalization: $2.2B
Industry: Biotechnology
This is a Bearish indicator signaling NTLA's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 49 similar cases where NTLA's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

NTLA saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for NTLA moved out of overbought territory on November 14, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In of the 57 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

NTLA moved below its 50-day moving average on October 23, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NTLA entered a downward trend on October 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NTLA's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 07, 2024. You may want to consider a long position or call options on NTLA as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on November 08, 2024. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.600) is normal, around the industry mean (14.655). P/E Ratio (0.000) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). NTLA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (33.670) is also within normal values, averaging (218.428).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com